Neoadjuvant Darovasertib in Primary Uveal Melanoma
Trial details
- Registry ID
- NCT07015190
- Phase
- Phase 3
Drug identity has not yet been verified against registry records
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| Neoadjuvant Darovasertib in Primary Uveal MelanomaNCT07015190 | IDEAYA Biosciences | Phase 3 | Recruiting | 2030-10Estimated |
| No regulatory events match this view.This does not mean no FDA events have occurred. |